ReproCell Stock

ReproCell Intangible Assets

The Intangible Assets of ReproCell (4978.T) as of Sep 4, 2026 is 18.70 M JPY. In the previous year, Intangible Assets was 13.36 M JPY — a change of 39.92% (higher).

Intangible Assets

18.70 MJPY

YoY

39.92%

Last updated:

Intangible Assets of ReproCell is 2026 18.70 M JPY. Intangible Assets of ReproCell was 2025 13.36 M JPY. It decreases by 39.92% higher compared to the previous year.

The ReproCell Intangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Intangible Assets
Date
Intangible Assets
Jan 1, 2018
1.49 M JPY
Jan 1, 2019
5.57 M JPY
Jan 1, 2020
21.21 M JPY
Jan 1, 2021
17.81 M JPY
Jan 1, 2022
12.84 M JPY
Jan 1, 2023
1.39 M JPY
Jan 1, 2024
13.36 M JPY
Jan 1, 2025
18.70 M JPY
The ReproCell Intangible Assets history
YEARIntangible AssetsYoY
18.70 MJPY+39.92%
13.36 MJPY+864.21%
1.39 MJPY-89.20%
12.84 MJPY-27.93%
17.81 MJPY-16.04%
21.21 MJPY+280.98%
5.57 MJPY+274.70%
1.49 MJPY-99.64%
411.55 MJPY-26.47%
559.68 MJPY-26.01%
756.41 MJPY+25,983.03%
2.90 MJPY
Access this data via the Eulerpool API

ReproCell Stock analysis

What does ReproCell do? ReproCell, Inc. is a company that was founded in 2003 and specializes in the research and manufacture of cell cultures. The company is based in Yokohama, Japan and operates worldwide. Its business model includes providing services and products to support research and development activities in the field of regenerative medicine and cell therapy. The company is divided into three main divisions: the Biorepository Division, which provides human cells and tissues for research purposes; the Cell Manufacturing Division, which develops production processes for cell therapy products; and the Drug Discovery Division, which supports drug development through screening and in vitro testing. ReproCell offers a variety of cell cultures, including stem cells from various sources, as well as related media, reagents, and tools for cultivation and application. In addition, the company offers services in cell therapy production, working closely with customers to provide customized and high-quality therapies. ReproCell also supports drug and compound research through screening and in vitro testing, with various platforms available for the identification and evaluation of new compounds. The company has a history of growth and has become a leading player in the field of cell culture and cell therapy production. In conclusion, ReproCell plays a significant role in regenerative medicine and cell therapy production, offering a wide range of products and services to support research and development in these areas. It is poised to continue its growth and contribute to the development of new therapies in the future. ReproCell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ReproCell stock

Intangible Assets of ReproCell is 18.70 M JPY in 2026.

Intangible Assets of ReproCell changed from 13.36 M JPY to 18.70 M JPY, representing a 39.92% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Intangible Assets ReproCell since 2006 – with annual values, charts, and detailed analysis.

Intangible assets are non-physical assets such as patents, trademarks, copyrights, and software. They can be significant value drivers for technology and pharmaceutical companies.

Intangible Assets's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Intangible Assets's ReproCell historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — ReproCell

All Key Metrics — ReproCell